z-logo
Premium
Oseltamivir for the treatment of H1N1 influenza during pregnancy
Author(s) -
Beigi RH,
Pillai VC,
Venkataramanan R,
Caritis SN
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.179
Subject(s) - oseltamivir , pregnancy , medicine , pandemic , intensive care medicine , adverse effect , drug , disease , h1n1 pandemic , covid-19 , obstetrics , infectious disease (medical specialty) , pharmacology , biology , genetics
Pregnancy heightens the risk of adverse outcomes from influenza infections. This is true for both seasonal epidemics as well as occasional pandemics. Seasonal influenza vaccines are the focus of disease prevention and are recommended for all pregnant women in any trimester of pregnancy and postpartum. Oseltamivir (Tamiflu) is currently the recommended and most commonly used pharmaceutical agent for influenza prophylaxis and treatment. Oseltamivir has been demonstrated to prevent disease after exposure, treat infected individuals, as well as lessen the likelihood of complications. The physiologic adaptations of pregnancy alter the pharmacokinetics of this important drug. Evidence of these alterations, knowledge gaps, and future investigative directions to fill these knowledge gaps are highlighted.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here